On the other hand, biomarkers such as ST2 and REG3α are potentially promising as single biomarkers correlating with therapy-resistant GVHD and GI-GVHD and as panels predicting six months of non-relapse mortality (NRM) (4). This evidence concerns the gene REG3A and graft versus host disease.